Anil Shah, MD
Cardiology · Santa Ana, CANPI 1619997368
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (56.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Angiodynamics, Inc. at 57.0% of the total. Reporting peaked in 2022 at $17,199 and has fallen 89.3% since, to $1,842 in 2025. Among cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 510 payments — averaging $96.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$28K
- Edwards Lifesciences$7K
- Medtronic$4K
- Novo Nordisk$2K
- Boston Scientific$2K
- Abbott$869
- plus $6K from 36 others
Across 31 payments — averaging $10,427 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$167K
- Boehringer Ingelheim$97K
- Novartis$15K
- Currax Pharmaceuticals LLC$14K
- AstraZeneca$13K
- Amgen$8K
- plus $10K from 2 others
What the payments were for
- Consulting fees$6,80014%
- Travel & lodging$2,9526%
- Food & beverage$11,78424%
- Other$27,50956%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 8 | $27,969 |
| Edwards Lifesciences | 4 | $6,800 |
| Medtronic(2 entities) | 64 | $4,047 |
| Novo Nordisk | 155 | $2,072 |
| Boston Scientific | 19 | $1,741 |
| Abbott | 17 | $869 |
| Novartis | 56 | $854 |
| Johnson & Johnson | 38 | $822 |
| Eli Lilly | 8 | $551 |
| Pfizer | 27 | $402 |
| Boehringer Ingelheim | 17 | $388 |
| Biotronik Inc. | 5 | $299 |
| Amgen | 13 | $253 |
| AstraZeneca | 14 | $250 |
| GE HealthCare | 2 | $193 |
| Lilly USA, LLC | 7 | $165 |
| Cardiovascular Systems Inc. | 6 | $153 |
| AbbVie | 1 | $119 |
| Bard Peripheral Vascular, Inc. | 2 | $113 |
| Sanofi-aventis U.S. LLC | 6 | $112 |
| Abiomed | 6 | $106 |
| Bayer | 4 | $83 |
| Regeneron | 1 | $82 |
| Merck | 4 | $68 |
| Lexicon Pharmaceuticals, Inc. | 3 | $58 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $58 |
| Imperative Care, Inc | 1 | $50 |
| Currax Pharmaceuticals LLC | 3 | $49 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Insulet Corporation | 1 | $34 |
| Atricure, Inc. | 1 | $32 |
| Kestra Medical Technology Services, Inc. | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Nevro Corp. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Bardy Diagnostics, Inc. | 1 | $17 |
| Cleerly, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Terumo Medical Corporation | 1 | $15 |
| GSK | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$27,436
- ELLIPSYS VASCULAR ACCESS SYSTEM$1,619
- ANGIOJET$880
- VenaCure 1470 Pro$453
- Reveal LINQ$420
- Azure$242
- XARELTO$213
- SYMPLICITY G3$129
- Pulsar-18 T3$126
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$125
- LUX-DX$120
- BOTOX COSMETIC$119
- Watchman$117
- Diamondback Peripheral$117
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$112
- ASSURITY$102
How this compares
$49,045 in reported general payments places this provider in the 95th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 85 | $64,681 |
| JardianceEmpagliflozin | 91 | $61,644 |
| EliquisApixaban | 88 | $55,438 |
| BrilintaTicagrelor | 53 | $28,328 |
| MounjaroTirzepatide | 24 | $25,659 |
| Repatha SureclickEvolocumab | 24 | $23,773 |
| OzempicSemaglutide | 26 | $22,536 |
| FarxigaDapagliflozin Propanediol | 20 | $19,130 |
| TrulicityDulaglutide | 13 | $12,987 |
| EntrestoSacubitril/Valsartan | 15 | $10,983 |
| JanuviaSitagliptin Phosphate | 15 | $9,825 |
| VascepaIcosapent Ethyl | 20 | $6,712 |
| Icosapent Ethyl | 16 | $4,681 |
| Varenicline Tartrate | 14 | $1,911 |
| Isosorbide Mononitrate | 31 | $1,231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $822 | $64,68185 claims |
| Boehringer IngelheimJardiance | $388 | $61,64491 claims |
| PfizerEliquis | $402 | $55,43888 claims |
| AstraZenecaBrilinta, Farxiga | $250 | $47,45873 claims |
| Lilly USA, LLCMounjaro, Trulicity | $165 | $38,64637 claims |
| Novo NordiskOzempic | $2,072 | $22,53626 claims |
| NovartisEntresto | $854 | $10,98315 claims |
| MerckJanuvia | $68 | $9,82515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 cardiology providers in California.
Other cardiology in Santa Ana
- Thomas KimSanta Ana$47K
- Amer ZarkaSanta Ana$6K
- Stephen CohenSanta Ana$6K
- Mahmoud Eslami-FarsaniSanta Ana$5K
- Bahram EslamiSanta Ana$4K
- Paul MeltzerSanta Ana$2K
- Norman LeporBeverly Hills$1.9M
- Sanjay KaulLos Angeles$1.1M
- Ramtin AgahMountain View$361K
- Jamshid MaddahiLos Angeles$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.